Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.53 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 5/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10349544 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP3A4CISD1SLC16A3 | |
| SCHEMBL3128764 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4ECYP3A4CISD1SLC16A3 | |
| SCHEMBL5173409 | 0.92 | TBXAS1 (0.58) | ALDH1A1KDM4ECYP3A4CISD1SLC16A3 | |
| Biphenyl SCHEMBL28775818 | 0.92 | ESR1 (0.50) | ALDH1A1KDM4ECYP3A4CISD1SLC16A3 | |
| SCHEMBL15056885 | 0.85 | TBXAS1 (0.52) | CYP3A4TBXAS1ESR1CYP2C9EPHX2 | |
| SCHEMBL2673966 | 0.85 | TBXAS1 (0.52) | CYP3A4TBXAS1ESR1CYP2C9EPHX2 | |
| SCHEMBL2271804 | 0.85 | TBXAS1 (0.56) | ALDH1A1CYP3A4TBXAS1ESR1CYP2C9 | |
| SCHEMBL2673972 | 0.85 | TBXAS1 (0.52) | CYP3A4TBXAS1ESR1CYP2C9EPHX2 | |
| SCHEMBL57683 | 0.84 | CYP3A4 (0.63) | ALDH1A1CYP3A4TBXAS1CYP2C9EPHX2 | |
| SCHEMBL2918640 | 0.84 | CYP3A4 (0.63) | ALDH1A1CYP3A4TBXAS1CYP2C9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10058534-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-08-28 | — | — | US | disclosed |
| US-20180169063-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2018-06-21 | — | — | US | disclosed |
| US-9931317-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-2958907-B1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-20170112805-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-9561211-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2017-02-07 | — | — | US | disclosed |
| US-20160184265-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| US-9321746-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | NOVARTIS AG (CH) | 2016-04-26 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2958907-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | Novartis AG (CH) | 2015-12-30 | — | — | EP | disclosed |
| EP-2931274-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Metabolic Solutions Development Company LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014130310-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | NOVARTIS AG (CH) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2012177956-A1 | PPAR-SPARING COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMAPNY, LLC (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184265-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, CYP19A1, GPER1 | ALDH1A1 1187/4885KDM4E 574/4885CYP3A4 80/4885 |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | ALDH1A1 465/4885KDM4E 3727/4885CYP3A4 299/4885 |
| US-10058534-B2 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | ESR1, CYP19A1, GPER1 | ALDH1A1 1187/4885KDM4E 574/4885CYP3A4 80/4885 |
| US-20170112805-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, CYP19A1, GPER1 | ALDH1A1 1187/4885KDM4E 574/4885CYP3A4 80/4885 |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | ALDH1A1 1510/4885KDM4E 2439/4885CYP3A4 685/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | ALDH1A1 465/4885KDM4E 3727/4885CYP3A4 299/4885 |
| US-20180169063-A1 | BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | ESR1, CYP19A1, GPER1 | ALDH1A1 1187/4885KDM4E 574/4885CYP3A4 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.